NCT02740920

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Studies have shown that the study drug, pembrolizumab, works by helping the immune system. In this way, pembrolizumab may help to slow the growth of melanoma or may cause cancer cells to die. Compared to standard treatments, pembrolizumab seems to lengthen the time patients lived overall and the time without their cancer getting worse.

Detailed description

The main purpose of this study is to find out if a type of CT (computed topography) scan can help to know if pembrolizumab is working. This CT scan (called Texture Analysis) looks at the tumour in fine detail. The use of this type of CT scan has not been studied in patients with metastatic melanoma. Investigators want to see if this CT scan will show if some patients being treated with pembrolizumab respond better than others. One of the other purposes is to compare the costs within this trial to costs of the standard of care.

Conditions

• Metastatic Melanoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab
PROCEDURE	CT Scan

Timeline

• Start date: 2017-01-10
• Primary completion: 2019-03-22
• Completion: 2019-09-30
• First posted: 2016-04-15
• Last updated: 2023-08-25
• Results posted: 2019-09-20

Locations

5 sites across 1 country: Canada